logo-loader

Shares of Conatus Pharmaceuticals slide on failure of liver-disease drug trial

Last updated: 09:00 05 Apr 2018 EDT, First published: 12:32 05 Apr 2018 EDT

Picture of drugs
The company says results support additional evaluation

Conatus Pharmaceuticals Inc. (NASDAQ:CNAT) shares declined today after the biotechnology company said a study of its drug to treat liver disease failed to meet the firm’s goals.

The stock plunged 32% to US$4.09 at 12:33 pm.

“Although the trial did not meet its primary endpoint,” the treatment “supports further evaluation,” the company said in a statement yesterday.

 

Ramp Metals Launches Drilling Program in Pursuit of High-Grade Nickel in...

Ramp Metals CEO Jordan Black joined Steve Darling from Proactive to introduce the company to the public domain and share exciting developments in the mining industry. With a background as a geotechnical engineer and experience in venture capital, including a notable role in taking GoldSpot...

1 hour, 27 minutes ago